David Langlais, professeur agrégé à l’Université McGill, fournit un aperçu de ses recherches sur les causes sous-jacentes de la fibrose pulmonaire. « Pour l’instant, il y a seulement deux médicaments qui sont approuvés, mais malheureusement ces médicaments-là ne guérissent pas la fibrose pulmonaire mais permettent de stabiliser dans certains cas le développement de la fibrose…

David Langlais, Associate Professor at McGill University, provides an overview of his research which investigates the underlying causes of pulmonary fibrosis. “In pulmonary fibrosis the arsenal for medications is really limited”, says Langlais. “There’s clearly an important need to identify new treatments for pulmonary fibrosis, and for this we need to understand the causes.” Learn…

Dre Charlene Fell, Dre Deborah Assayag et Dre Amanda Grant-Orser, pneumologues, discutent du rôle vital de l’oxygénothérapie pour améliorer la qualité de vie des patients, et de la nécessité d’un accès égal à l’échelle du pays. Lisez les rappor ts de la FCFP sur l’accès à l’oxygénothérapie au Canada En savoir plus sur l’oxygénothérapie pour…

Tune in as Dr. Kirsten Nesset shares the impact made by her CPFF Robert Davidson Fellowship, and gives an update on her research project that explores how frailty might impact patient engagement and satisfaction in remote monitoring programs. Respirologist Dr. Nesset, CPFF Robert Davidson Fellowship recipient, is undertaking her fellowship at the Firestone Institute for…

Tune in as Dr. Shane Shapera shares how CPFF Robert Davidson Fellowships have played a critical role in starting up University Health Network’s (UHN’s) ILD research program, supporting the first generation of Interstitial Lung Disease (ILD)-trained clinicians in Canada. As a direct result of CPFF Robert Davidson Fellowships, academic respirologists will continue ILD research for…

In this webinar, Paralympians Brianna Hennessy, Candice Combdon, and Jessica Lewis, each of whom overcame life-altering physical and emotional challenges, share their journeys and inspire hope. Life is filled with bumps and things we wish we could change but the beauty of it is finding joy despite those things. Brianna Hennessy is an accomplished athlete…

This presentation, led by Dr. Donald Zoz MD, senior clinical program leader at Boehringer Ingelheim, provides some insight into FIBRONEER-IPF, a Phase 3 Clinical Trial. The goal of FIBRONEER-IPF Phase 3 Clinical Trial is to evaluate the efficacy, safety, and tolerability of the compound BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis…